RareLabs, a division of AlphaRose Therapeutics, named Rob Freishtat, MD as CEO. Charles Hirner joined NuvemRx as SVP of ...
Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, delaying generic competition for its blockbuster ATTR-CM drug Vyndamax until 2031. The move preserves ...
Hosted on MSN
Pfizer settles to delay Vyndamax generics until 2031
Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout ...
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its ...
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results